Greenberg Traurig Patent Attorney, Dr. Fang Xie, to Speak at BBA Conference on U.S.-China Competition and Collaboration

Share Article

On April 18, 2017, Dr. Fang Xie, patent attorney and of counsel in Greenberg Traurig, LLP’s Boston office, will speak at the Boston Bar Association (BBA) conference, “Intellectual Property (IP) Protection In China: Successes and Challenges.”

On April 18, 2017, Dr. Fang Xie, patent attorney and of counsel in Greenberg Traurig, LLP’s Boston office, will speak at the Boston Bar Association (BBA) conference, “Intellectual Property (IP) Protection In China: Successes and Challenges.” The program will bring together thought leaders and policymakers on China IP issues from U.S. government and academics to share their insights on critical issues involving China IP that will benefit U.S. IP right holders.

From 11:30 a.m. - 12:30 p.m., Dr. Xie will moderate the panel, “U.S.-China: Competition and Collaboration – Strategies for the Years Ahead,” which will cover topics such as cross-border collaborative R&D and licensing, how to bridge and leverage the difference in patent laws between U.S. and China, antitrust consideration when doing deals in both countries, as well as what the data says about U.S.-China collaboration and future prospects.

The conference is a collaboration between the U.S. Patent Trademark Office, BBA, and the U.S. Commercial Service for Massachusetts.

Dr. Xie is co-leader of Greenberg Traurig’s Biotechnology and Pharmaceutical Industry Group within the firm’s global Life Sciences & Medical Technology Group. Recently listed in IAM Strategy 300 – The World’s Leading IP Strategists, Dr. Xie focuses her practice on life sciences and technology‐driven transactions involving the establishing, licensing, sharing, developing, and monetizing various intellectual property rights. She has broad experience in worldwide patent and trademark portfolio development, intellectual property due diligence, licensing and technology transfer, patentability and product clearance studies, patent infringement and validity analyses, freedom to operate evaluations, as well as intellectual property litigation and pre-litigation counseling.

About Greenberg Traurig’s Life Sciences & Medical Technology Group

Greenberg Traurig’s Life Sciences & Medical Technology Group advises clients ranging from startups to large multinational public companies to leading research institutions. The group’s attorneys work closely with clients, providing innovative legal counsel to help them achieve their objectives – from discovery through commercialization and product marketing. As part of the group, the Biotechnology and Pharmaceutical Industry Group focuses on advising clients in the biotechnology and pharmaceutical sectors.

About Greenberg Traurig, LLP

Greenberg Traurig, LLP (GTLaw) has more than 2,000 attorneys in 38 offices in the United States, Latin America, Europe, Asia and the Middle East and is celebrating its 50th anniversary. A single entity worldwide, GTLaw has been recognized for its philanthropic giving, was named the second largest firm in the U.S. by Law360 in 2016, and among the Top 20 on the 2016 Am Law Global 100. Web: http://www.gtlaw.com Twitter: @GT_Law.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lourdes Brezo Martinez
Greenberg Traurig
+1 (212) 801-2131
Email >
Visit website